CDIM 9
Basal-like / Triple-Negative Breast Cancer
PreclinicalActive
Key Facts
About Plantacor
Plantacor is a preclinical-stage biotech leveraging natural product chemistry to develop novel oncology therapeutics. The company has established a proprietary formulation platform to enhance the delivery and reduce the toxicity of difficult-to-solubilize small molecules. Its lead program, CDIM 9, is in late-stage preclinical development for basal-like breast cancer, an aggressive subtype with limited treatment options. Plantacor operates from College Station, Texas, benefiting from proximity to major research institutions and has utilized over $9M in grant-funded research to build its pipeline.
View full company profile